APOE ε4 influences β‐amyloid deposition in primary progressive aphasia and speech apraxia. Issue 6 (28th June 2014)

• Record Type: Journal Article
• Authors: Josephs, Keith A.; Duffy, Joseph R.; Strand, Edythe A.; Machulda, Mary M.; Senjem, Matthew L.; Lowe, Val J.; Jack, Clifford R.; Whitwell, Jennifer L.
• Is Part Of: Alzheimer's & dementia. Volume 10:Issue 6(2014)
• Page Start: 630
• Page End: 636
• Publication Date: 2014-06-28
• Subjects: Apolipoprotein -- Pittsburgh compound B -- Primary progressive aphasia -- Logopenic aphasia -- Speech apraxia; Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1016/j.jalz.2014.03.004
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Apolipoprotein E ε4 ( APOE ε4) is a risk factor for β‐amyloid deposition in Alzheimer's disease dementia. Its influence on β‐amyloid deposition in speech and language disorders, including primary progressive aphasia (PPA), is unclear. Methods: One hundred thirty subjects with PPA or progressive speech apraxia underwent APOE genotyping and Pittsburgh compound B (PiB) PET scanning. The relationship between APOE ε4 and PiB status, as well as severity and regional distribution of PiB, was assessed. Results: Forty‐five subjects had an APOE ε4 allele and 60 subjects were PiB‐positive. The odds ratio for a subject with APOE ε4 being PiB‐positive compared with a subject without APOE ε4 being PiB‐positive was 10.2 (95% confidence interval, 4.4–25.5; P < .0001). The APOE ε4 allele did not influence regional PiB distribution or severity. Conclusion: APOE ε4 increases the risk of β‐amyloid deposition in PPA and progressive speech apraxia but does not influence regional β‐amyloid distribution or severity.